BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 177 filers reported holding BLUEBIRD BIO INC in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,541 | -5.4% | 507 | +2.4% | 0.00% | – |
| Q2 2023 | $1,629 | +62.6% | 495 | +57.1% | 0.00% | – |
| Q1 2023 | $1,002 | -66.9% | 315 | -27.9% | 0.00% | – |
| Q4 2022 | $3,024 | +51.2% | 437 | +50.7% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 290 | +12.4% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 258 | +2.8% | 0.00% | – |
| Q4 2021 | $3,000 | -40.0% | 251 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -89.4% | 251 | -83.1% | 0.00% | -100.0% |
| Q2 2021 | $47,000 | +9.3% | 1,485 | +3.2% | 0.00% | 0.0% |
| Q1 2021 | $43,000 | -30.6% | 1,439 | +0.8% | 0.00% | -33.3% |
| Q4 2020 | $62,000 | +785.7% | 1,428 | +1080.2% | 0.00% | – |
| Q3 2020 | $7,000 | +40.0% | 121 | +39.1% | 0.00% | – |
| Q2 2020 | $5,000 | +400.0% | 87 | +569.2% | 0.00% | – |
| Q1 2020 | $1,000 | -75.0% | 13 | -74.5% | 0.00% | – |
| Q4 2019 | $4,000 | -98.6% | 51 | -96.9% | 0.00% | -100.0% |
| Q4 2017 | $294,000 | – | 1,653 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sessa Capital IM, L.P. | 1,834,965 | $35,066,000 | 1.72% |
| Birchview Capital, LP | 84,000 | $1,605,000 | 1.09% |
| ARMISTICE CAPITAL, LLC | 2,472,000 | $47,240,000 | 0.80% |
| EcoR1 Capital, LLC | 802,507 | $15,336,000 | 0.53% |
| Parametrica Management Ltd | 36,919 | $706,000 | 0.53% |
| Bain Capital Life Sciences Investors, LLC | 538,179 | $7,239,000 | 0.45% |
| APPLETON GROUP, LLC | 19,495 | $373,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 175,587 | $3,355,000 | 0.30% |
| Quinn Opportunity Partners LLC | 230,100 | $4,397,000 | 0.28% |
| PDT Partners, LLC | 171,700 | $3,281,000 | 0.24% |